# Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study

Study · id `cardio:ct-nct05554822` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05554822](<https://clinicaltrials.gov/study/NCT05554822>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05554822

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 574 participants.

## Technical summary

Registry record NCT05554822. Randomized; no masking; primary purpose treatment. Start 2021-06-14 (actual); primary completion 2023-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 574 participants (planned count; ClinicalTrials.gov record NCT05554822, source copy `cardio:ctgov-nct05554822-2022-10-03`, retrieved 2026-10-26)
- Started: 2021-06-14 (actual) (ClinicalTrials.gov record NCT05554822, source copy `cardio:ctgov-nct05554822-2022-10-03`, retrieved 2026-10-26)
- Primary completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05554822, source copy `cardio:ctgov-nct05554822-2022-10-03`, retrieved 2026-10-26)
- Completion: 2023-12-31 (anticipated) (ClinicalTrials.gov record NCT05554822, source copy `cardio:ctgov-nct05554822-2022-10-03`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT05554822, source copy `cardio:ctgov-nct05554822-2022-10-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05554822-2022-10-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: Head-to-head Comparison of Single Versus Dual Antiplatelet Treatment Strategy After Percutaneous Left Atrial Appendage Closure: a Multicenter, Randomized Study
- Acronym: ARMYDA-AMULET
- Condition: Left Atrial Appendage Occlusion
- Condition: Antiplatelet Therapy
- Intervention (Drug): Aspirin 100mg
- Intervention (Drug): Aspirin 100 mg OD plus clopidogrel 75 mg OD
- Lead sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita
- Lead sponsor class: OTHER
- Collaborator: Abbott Medical Devices
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Azienda Ospedaliero Universitaria Maggiore della Carita (`cardio:org-azienda-ospedaliero-universitaria-maggiore-della-carita`)
- Registry lists this organization as a collaborator: Abbott (`cardio:abbott`)

## Provenance

Content hash: 07580171a59f6bf4824fd82f9baea15653920e002e146b8fc54c613229da56c1
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
